Condition: Solid Tumor · Lymphoma · Sponsor: Canwell Biotech Limited
A phase 1, dose escalation, open-label study of intratumoral CAN2109 in subjects with unstable or metastatic advanced solid tumors or lymphomas.
This description comes directly from the study's public registry record.
Herui Yao, MD · +86 020-34070412 · yaoherui@mail.sysu.edu.cn
Erwei Song, MD · +86 020 81332507 · songew@mail.sysu.edu.cn
Always discuss trial participation with your own doctor first.
| Sun Yat-Sen University Sun Yat-Sen Memorial Hospital | Guangzhou, Guangdong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06332430